ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Tempest Therpeutics Inc

Tempest Therpeutics Inc (TPST)

1.04
0.04
(4.00%)
Closed November 06 4:00PM
1.03
-0.01
(-0.96%)
After Hours: 7:57PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.03
Bid
1.02
Ask
1.03
Volume
1,864,673
0.9519 Day's Range 1.04
0.8637 52 Week Range 6.00
Market Cap
Previous Close
1.00
Open
1.00
Last Trade Time
Financial Volume
$ 1,857,793
VWAP
0.99631
Average Volume (3m)
4,905,785
Shares Outstanding
25,207,792
Dividend Yield
-
PE Ratio
-0.89
Earnings Per Share (EPS)
-1.17
Revenue
-
Net Profit
-29.49M

About Tempest Therpeutics Inc

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Tempest Therpeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TPST. The last closing price for Tempest Therpeutics was $1. Over the last year, Tempest Therpeutics shares have traded in a share price range of $ 0.8637 to $ 6.00.

Tempest Therpeutics currently has 25,207,792 shares outstanding. The market capitalization of Tempest Therpeutics is $25.21 million. Tempest Therpeutics has a price to earnings ratio (PE ratio) of -0.89.

TPST Latest News

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Extends Limited Duration Stockholder Rights Plan

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (β€œTempest” or the β€œCompany”), a clinical-stage biotechnology company developing first-in-classi...

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs

BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance

BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.08238.684182758260.94771.0450.863733456330.95052217CS
4-0.36-25.89928057551.391.590.863781940761.08925282CS
12-0.06-5.504587155961.092.180.863749057851.27510689CS
26-2.72-72.53333333333.753.790.863728650301.42365171CS
52-2.69-72.3118279573.7260.863722397992.2656945CS
156-10.92-91.380753138111.9512.30.1715841044.40712232CS
260-12.78-92.541636495313.81410.1714601784.93238221CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CONLGraniteShares ETF Trust GraniteShares
$ 43.12
(61.62%)
24.47M
ARBBARB IOT Group Ltd
$ 0.802709
(42.20%)
224.6M
ELWSEarlyworks Co Ltd
$ 6.00
(41.18%)
6.05M
CTKBCytek Biosciences Inc
$ 7.40
(36.03%)
4.17M
TMCITreace Medical Concepts Inc
$ 7.78
(35.07%)
3.13M
BNOXBionomics Ltd
$ 0.2839
(-42.41%)
17.48M
VSTEVast Renewable Ltd
$ 3.09
(-42.35%)
2.65M
ZCARZoomcar Holdings Inc
$ 7.6899
(-41.74%)
1.3M
ZVSAZyVersa Therapeutics Inc
$ 1.5242
(-39.99%)
2.05M
TNGXTango Therapeutics Inc
$ 3.22
(-37.84%)
14.72M
ELABElevai Labs Inc
$ 0.0173
(-19.16%)
303.44M
NVDANVIDIA Corporation
$ 145.61
(4.07%)
232.47M
ARBBARB IOT Group Ltd
$ 0.802709
(42.20%)
224.6M
SQQQProShares UltraPro Short QQQ
$ 6.6503
(-8.02%)
214.38M
DJTTrump Media and Technology Group Corporation
$ 35.955
(5.94%)
171.54M

TPST Discussion

View Posts
aBeezlee aBeezlee 2 hours ago
Not a bad recovery. Will see if an ER or business report is released, then decide to sell or not.
πŸ‘οΈ0
Monksdream Monksdream 2 days ago
TPST , new 52 week low
πŸ‘οΈ0
stockyupydowny stockyupydowny 3 days ago
Agreed, we will see positive news and a boost in price prior to the split..... the higher the price the lower the split IF its even required. Should they get positive news and more support from ROCHE this can rocket and then cancel split... that's moon time!
👍️ 1
georgie18 georgie18 6 days ago
We shall see...🥳
πŸ‘οΈ0
aBeezlee aBeezlee 6 days ago
1 to 2, or 1 to 15 RS. The split doesn't make sense unless a notable event is coming. Negative sentiment will simply beat it down, and kill existing holders further.

I'm under the impression dilution is coming.
πŸ‘οΈ0
georgie18 georgie18 1 week ago
Yes I did...will buy back when the dust settles...🥳...made great profit with TPST and if the reverse should happen it should put this stock in the $40...imo...we shall see...
👍 1
rocketeer357 rocketeer357 1 week ago
Did you sell on the 14a news?
πŸ‘οΈ0
georgie18 georgie18 1 week ago
You saw the 14a...🥳
πŸ‘οΈ0
The GidDy uP Kid The GidDy uP Kid 1 week ago
aDDed after hours sub $1 range...
πŸ‘οΈ0
aBeezlee aBeezlee 1 week ago
RS was unexpected for something without a delisting notice. Perhaps something planned to prevent a takeover. Hmm...
πŸ‘οΈ0
georgie18 georgie18 1 week ago
TPST...14A Filing...Approval of a series of alternate amendments to our Restated Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-15, inclusive, with such ratio to be determined by our Board of Directors in its sole discretion (β€œReverse Stock Split Proposal” or β€œProposal 1”).
What if another matter is properly brought before the Special Meeting?
👍 1
georgie18 georgie18 1 week ago
TPST....85...A/H Dip...🥳
πŸ‘οΈ0
georgie18 georgie18 1 week ago
Nice to have you with me on it...🥳
πŸ‘οΈ0
tw0122 tw0122 1 week ago
One of your GM favorites been adding myself low $1s for next blastoff to $2s ...newsand trials
πŸ‘οΈ0
georgie18 georgie18 1 week ago
TPST...$1.16s in the P/M...🥳

georgie18

Member Level
Re: georgie18 post# 614

Friday, October 25, 2024 12:38:28 PM

Post#
615
of 617
TPST...$1.12s clearing here...🥳Reversing...

georgie18

Member Level
Re: georgie18 post# 662364

Friday, October 25, 2024 9:43:40 AM

Post#
662715
of 662771
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
aBeezlee aBeezlee 1 week ago
Long hold. Roche wouldn't supply them with goods if they felt phase 3 would fail. Looking for $2 on positive results.
πŸ‘οΈ0
georgie18 georgie18 2 weeks ago
Have a Great Weekend Y'all...🥳
πŸ‘οΈ0
georgie18 georgie18 2 weeks ago
TPST...$1.12s clearing here...🥳Reversing...

georgie18

Member Level
Re: georgie18 post# 662364

Friday, October 25, 2024 9:43:40 AM

Post#
662715
of 662771
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
georgie18 georgie18 2 weeks ago
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
georgie18 georgie18 2 weeks ago
TPST...Loaded $1.03 to $1.05s...🥳
πŸ‘οΈ0
Xunefox Xunefox 3 weeks ago
May be an AH show after all
πŸ‘οΈ0
aBeezlee aBeezlee 3 weeks ago
Yup TPST! I have RNAZ on list too. Buying both with next check. 🔥
πŸ‘οΈ0
georgie18 georgie18 3 weeks ago
TPST...$1.22...🥳...Dipping it to fill the Open Gap...another great add spot...Ran to $1.60 range in the A/H ...

georgie18

Member Level
Re: georgie18 post# 384329

Tuesday, October 15, 2024 3:37:36 PM

Post#
384411
of 384426
TPST...$1.14clearing here...🥳

georgie18

Member Level
Re: None

Friday, October 11, 2024 9:46:27 AM

Post#
603
of 603
TPST...99...great add spot....🥳
πŸ‘οΈ0
georgie18 georgie18 3 weeks ago
TPST …yes beauty move in the A/H…🥳
πŸ‘οΈ0
Vitamin310 Vitamin310 3 weeks ago
I’m in!
πŸ‘οΈ0
Money hunt Money hunt 3 weeks ago
TPST smell green dude!!! RNAZ Next DRUG
πŸ‘οΈ0
The GidDy uP Kid The GidDy uP Kid 3 weeks ago
Nice Georgie… TPST $1.61 after hours close…
πŸ‘οΈ0
aBeezlee aBeezlee 3 weeks ago
The next DRUG?!
πŸ‘οΈ0
georgie18 georgie18 3 weeks ago
TPST...$1.14clearing here...🥳

georgie18

Member Level
Re: None

Friday, October 11, 2024 9:46:27 AM

Post#
603
of 603
TPST...99...great add spot....🥳
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
TPST...99...great add spot....🥳
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 weeks ago
TPST: Nope!! Cancer is NOT trending anymore, CLOWN!!! (Nice call, IDIOT!!!)
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
TPST...$1.09...Great add opportunity...imo...we shall see...🥳
πŸ‘οΈ0
georgie18 georgie18 4 weeks ago
TPST...$1.59...from the .90 range bottom...🥳BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.

georgie18

Member Level
Re: None

Friday, August 09, 2024 2:43:01 PM

Post#
652989
of 660804
TPST...$1.16...Taking a hit on earnings...adding more down here...🥳
πŸ‘οΈ0
TrendTrade2016 TrendTrade2016 4 weeks ago
july shelf offering allows lender to sell stock at anytime
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 weeks ago
TPST: Hopefully!! (But is "Cancer" TRENDING anymore??)
πŸ‘οΈ0
tw0122 tw0122 4 weeks ago
TPST 1.82 +’35% resistance at 1.85 looks good again until 2.01- 2.23 resistance then big jump to 2.91

a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.
Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. This agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study. Tempest retains all development and commercial rights to amezalpat.
πŸ‘οΈ0
Invest-in-America Invest-in-America 4 weeks ago
TPST: I'm in!! Are you?? (Heck, goin' to Phase-3 with Roche?? I'll jump-on for ride!!)

πŸ‘οΈ0
Invest-in-America Invest-in-America 4 weeks ago
TPST: Some Roche agreement news.
πŸ‘οΈ0
georgie18 georgie18 1 month ago
TPST...$1.44s clearing on the 50MA Break...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
TPST...$1.50s clearing into the close...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
Have a Great Weekend Y'all...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
Nice...will be very pleased with 1/2 that target...🥳
πŸ‘οΈ0
glens0 glens0 2 months ago
Bought a starter today.
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
12:54 PM ET 8/15/24 | Dow Jones
πŸ‘οΈ0
georgie18 georgie18 2 months ago
TPST...$1.35...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
TPST...$1.44...HOD...🥳
πŸ‘οΈ0
georgie18 georgie18 2 months ago
TPST...$1.50...Off the .90 range dip...🥳...was $6 recently...setting up for a Breakout...imo...we shall see...
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...1.4995...HOD...Beauty move off the .90 range dip...🥳Was $6 a couple of months ago...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.60 off the $2 plus move from .90 range...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$2.00 ...Clearing here...🥳
πŸ‘οΈ0
georgie18 georgie18 3 months ago
TPST...$1.24...🥳...BRISBANE, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma (HCC).

"We are thrilled with the positive outcome of our end-of-Phase 2 meeting with the FDA,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest. β€œTempest and the FDA are in broad agreement on all major aspects of the proposed pivotal Phase 3 clinical trial for amezalpat in patients with hepatocellular carcinoma in the first line setting. This planned Phase 3 study closely mirrors the randomized Phase 2 study and the strongly favorable hazard ratio for overall survival observed at top-line analysis of the Phase 2, confirmed at the latest survival follow-up, give us confidence in the potential success of the Phase 3.”

Key outcomes of the FDA meeting include:

Agreement on Phase 3 study design, including the standard-of-care control arm and the primary and secondary study endpoints
Agreement on appropriateness of the current amezalpat dose and schedule for the Phase 3 study
Agreement on the Phase 3 statistical plan including a pre-specified early efficacy analysis that the company currently estimates could shorten the time to primary analysis by up to 8 months
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock